Three semaglutide-containing options are currently available to U.S. patients seeking weight loss treatment: Wegovy (semaglutide 2.4 mg), Ozempic (semaglutide 0.5–2 mg), and compounded semaglutide from licensed pharmacy facilities. All three contain the same active molecule. The differences in clinical evidence, regulatory status, dosing, and pricing are substantial — and they matter for your decision.
The essential distinction upfront
Wegovy is the only FDA-approved semaglutide formulation for obesity. Ozempic is FDA-approved for type 2 diabetes only — prescribing it for weight loss is off-label. Compounded semaglutide contains the same active ingredient but is not FDA-approved as a finished product. Each has a different evidence base, regulatory status, and risk profile.
Wegovy (Semaglutide 2.4 mg) — The FDA-Approved Obesity Standard
Wegovy received FDA approval for chronic weight management in June 2021. The approval was based on the STEP trial program — four phase 3 randomized controlled trials involving over 4,500 participants across multiple clinical profiles.
The STEP 1 trial (n=1,961, non-diabetic adults with obesity) demonstrated mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo (p<0.001).1 86.4% of Wegovy participants achieved at least 5% weight loss; 69.1% achieved at least 10%; 50.5% achieved at least 15%.
The SELECT cardiovascular outcomes trial (n=17,604) — the landmark finding of 2023 — demonstrated Wegovy 2.4 mg reduced the composite cardiovascular endpoint (CV death, nonfatal MI, nonfatal stroke) by 20% over ~40 months in patients with preexisting cardiovascular disease and overweight or obesity without diabetes (HR 0.80, 95% CI 0.72–0.90, p<0.001).2 This is the only semaglutide formulation with cardiovascular outcomes trial data in non-diabetic patients.
Find a GLP-1 option matched to your state and budget in 60 seconds.
Get My Match →Ozempic (Semaglutide 0.5–2 mg) — Diabetes-Approved, Often Prescribed Off-Label
Ozempic (semaglutide) is FDA-approved for type 2 diabetes management at doses of 0.5 mg, 1 mg, and 2 mg weekly. It is not FDA-approved for weight management, though physicians frequently prescribe it off-label for this purpose — a legal but regulatory distinction that has clinical implications.
At the 1 mg dose used in diabetes trials, semaglutide produced mean weight losses of approximately 6.1% in the SUSTAIN trials.3 At the 2 mg dose (the highest approved diabetes dose), weight loss outcomes are closer to — but do not reach — the 14.9% achieved with Wegovy's 2.4 mg obesity-specific dose. The higher dose matters clinically.
The SUSTAIN-6 cardiovascular outcomes trial (n=3,297, patients with type 2 diabetes and high CV risk) found semaglutide 1 mg reduced the three-point MACE composite by 26%.4 However, these data apply to diabetic patients — the SELECT data in non-diabetic patients comes from Wegovy specifically.
Compounded Semaglutide — Same Molecule, Different Evidence
Compounded semaglutide uses pharmaceutical-grade semaglutide API produced at licensed compounding facilities. The active pharmaceutical ingredient is identical; the finished product has not undergone FDA approval or the clinical trial program that supports Wegovy's labeling.
| Feature | Wegovy 2.4 mg | Ozempic (off-label) | Compounded |
|---|---|---|---|
| FDA approval for obesity | ✓ Yes | ✗ No (diabetes only) | ✗ No |
| Pivotal obesity RCT data | STEP 1–4 (4,500+ pts) | Limited (diabetes trials) | None (extrapolated) |
| CV outcomes trial | SELECT (17,604 pts) | SUSTAIN-6 (diabetes pts) | None |
| Manufacturing oversight | FDA CGMP (Novo Nordisk) | FDA CGMP (Novo Nordisk) | Varies (503A/503B) |
| Cash-pay price | ~$1,349/month | ~$1,000/month (off-label) | $149–$350/month |
| Insurance coverage | Yes (with prior auth) | Yes (for diabetes) | Generally no |
How Physicians Actually Make This Decision
Patients with cardiovascular disease: Prioritize brand-name Wegovy. The SELECT trial's 20% reduction in MACE applies to this formulation specifically. Pursue prior authorization aggressively before considering compounded alternatives.
Patients with type 2 diabetes: Ozempic is the appropriate on-label choice. It addresses both diabetes and provides meaningful weight reduction, with cardiovascular benefit demonstrated in SUSTAIN-6.
Patients without insurance coverage, no significant cardiovascular risk: A physician-supervised compounded program from a 503B facility is a clinically reasonable starting point. Begin while exploring insurance coverage options.
To see which options are available in your state at your budget, use the free matching tool.